Better valve placement for severe aortic stenosis
Part of Heart & circulation clinical trials.
This trial tests a new way to position the Evolut FX+ valve in people with severe aortic stenosis. The goal is to improve how the valve lines up with your own heart structure, which may help it work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe aortic stenosis and your heart team has recommended a valve replacement procedure (TAVI).
- You are 65 years old or older.
- Your heart team plans to use the Evolut FX+ self-expanding valve for your procedure.
- You do not have severe blood vessel disease in your legs that would block the insertion of the valve through your leg artery.
- You have not had a previous aortic valve replacement, and your aortic valve has two flaps (bicuspid) instead of three.
- Your kidney function is not severely reduced (estimated glomerular filtration rate is 30 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two types of replacement heart valves (self-expanding and balloon-expanding) in people who have severe aortic stenosis (tight heart valve) and an enlarged aorta (the main blood vessel from the heart). The goal is to see which valve type works better for these patients.
This trial looks at placing a new aortic valve through the groin (transfemoral) without needing on-site heart surgery for people who are considered very high risk for standard open-heart valve surgery. It aims to measure early outcomes to see how safe and effective this approach is for frail or complex patients.
This trial is testing a new heart valve system (Medtronic Evolut FX+) for people with severe aortic stenosis—a condition where the heart's main valve is narrowed. The study aims to see how well the valve works and improve your care journey.
This study checks whether an “investigational” transcatheter aortic valve is safe and works well for people with severe, calcified aortic stenosis (a stiff, narrowed heart valve). It may help improve valve function and symptoms, but you must meet specific heart, scan, and health-status requirements.
This trial is testing a better way to position a new heart valve during a TAVI procedure. The goal is to help the valve work as well as possible for people with severe aortic stenosis.
This trial compares two of the newest transcatheter aortic valve devices—the SAPIEN 3 Ultra Resilia and Evolut FX—to see which works better for patients with severe aortic stenosis (a narrowed aortic valve). Both devices are placed through a catheter without open surgery.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.